ReviewCureus2019
The Hypervirulent Strain of Clostridium Difficile: NAP1/B1/027 - A Brief Overview.
Review in Cureus, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cadazolid vs Vancomycin for the Treatment of Clostridioides difficile Infection: Systematic Review with Meta-analysis.Current clinical pharmacology · 2020Pooled it
- Clinical Characteristics and Risk Factors ofJournal of clinical medicine · 2026Article
- Addressing Unmet Needs inCurrent medicinal chemistry · 2026Review
- Extraintestinal Manifestations ofAntibiotics (Basel, Switzerland) · 2025Review
- Synthesis of PSI Oligosaccharide for the Development of Total Synthetic Vaccine againstThe Journal of organic chemistry · 2025Article
- Evaluating Vancomycin Monotherapy and Dual Therapy with Nifuroxazide for Medium-Severe Clostridioides Difficile Infection.Antibiotics (Basel, Switzerland) · 2025Article
- AApplied and environmental microbiology · 2025Article
- Dominance of toxigenicFrontiers in microbiology · 2025Article
- Prevalence of toxigenicThe Libyan journal of medicine · 2024Article
- Development of multi-epitope mRNA vaccine againstSynthetic and systems biotechnology · 2024Article
- Chemical optimization and derivatization of micrococcin p2 to target multiple bacterial infections: new antibiotics from thiopeptides.World journal of microbiology & biotechnology · 2024Review
- "Antibiotics (Basel, Switzerland) · 2024Article
- Environmental and Nutritional Parameters Modulating Genetic Expression for Virulence Factors ofAntibiotics (Basel, Switzerland) · 2024Review
- Genomic surveillance ofmBio · 2024Article
- Review
- Defined microbial communities and their soluble products protect mice from Clostridioides difficile infection.Communications biology · 2024Article
- Update on Commonly Used Molecular Typing Methods forMicroorganisms · 2023Review
- Article
- Genistein Inhibits Clostridioides difficile Infection via Estrogen Receptors and Lysine-Deficient Protein Kinase 1.The Journal of infectious diseases · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridium difficile is a gram-positive bacterium notorious for causing epidemic diarrhea globally with a significant health burden. The pathogen is clinically challenging with increasing antibiotic resistance and recurrence rate. We provide here an in-depth review of one particular strain/ribotype 027, commonly known as NAP1/B1/027 or North American pulsed-field gel electrophoresis type 1, restriction endonuclease analysis type B1, polymerase chain reaction ribotype 027, which has shown a much higher recurrence rate than other strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.